WebMay 13, 2024 · SAN DIEGO, May 13, 2024 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to … WebJan 19, 2024 · Cardiff Oncology's attempt to hit all subtypes of Kras-mutated colorectal cancer with its PLK1 inhibitor onvansertib is being tested in an ongoing second-line study, but the latest data cut makes for disappointing reading. Responses waned on last year, in confirmed and unconfirmed analyses alike.

Asco-GI 2024 – Cardiff’s data weaken, but pivotal plans are afoot

WebOct 15, 2024 · This is an ongoing Phase 1b/2 trial for onvansertib in combination with standard-of-care (SOC) as second-line therapy in patients with KRAS-mutated … WebMay 13, 2024 · Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. gambling house galveston

Cardiff Oncology Presents Findings from its Expanded Access …

WebJun 7, 2024 · Cardiff Oncology is the first to correctly target PLK1, a target in several solid tumors, in all KRAS-mutated cancers. Learn more about CRDF stock here. WebJan 31, 2024 · Cardiff Oncology ( CRDF -3.89%) is an oncology specialist that had a fantastic year in 2024. The market is excited about the biotech's lead molecule, onvansertib, because it might work to... WebA Phase 1b/2 Study of the Polo-like Kinase 1 (PLK1) inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second-Line Treatment of Patients with KRAS … gambling how do i come clean